Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
48
PTGX Quote, Financials, Valuation and Earnings
Last price:
$40.57
Seasonality move
:
28.98%
Day range:
$38.91 - $41.68
52-week range:
$21.43 - $48.89
Dividend yield:
0%
P/E ratio:
15.60x
P/S ratio:
7.92x
P/B ratio:
4.65x
Volume:
2.3M
Avg. volume:
836.9K
1-year change:
99.95%
Market cap:
$2.5B
Revenue:
$60M
EPS (TTM):
$2.66
Protagonist Therapeutics SEC Filings
| Company | Filed | Form Type | Description | |
|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics
|
11/02/2023 | 10-Q | 10-Q filing on 11/02/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/03/2023 | 10-Q | 10-Q filing on 08/03/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/04/2023 | 10-Q | 10-Q filing on 05/04/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/08/2022 | 10-Q | 10-Q filing on 11/08/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/04/2022 | 10-Q | 10-Q filing on 08/04/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/05/2022 | 10-Q | 10-Q filing on 05/05/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/03/2021 | 10-Q | 10-Q filing on 11/03/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/04/2021 | 10-Q | 10-Q filing on 08/04/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/04/2021 | 10-Q | 10-Q filing on 05/04/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/04/2020 | 10-Q | 10-Q filing on 11/04/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/06/2020 | 10-Q | 10-Q filing on 08/06/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/07/2020 | 10-Q | 10-Q filing on 05/07/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/10/2020 | 10-K | 10-K filing on 03/10/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/06/2019 | 10-Q | 10-Q filing on 11/06/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/07/2019 | 10-Q | 10-Q filing on 08/07/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/08/2019 | 10-Q | 10-Q filing on 05/08/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/12/2019 | 10-K | 10-K filing on 03/12/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/06/2018 | 10-Q | 10-Q filing on 11/06/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/07/2018 | 10-Q | 10-Q filing on 08/07/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/09/2018 | 10-Q | 10-Q filing on 05/09/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/07/2018 | 10-K | 10-K filing on 03/07/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/07/2017 | 10-Q | 10-Q filing on 11/07/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/08/2017 | 10-Q | 10-Q filing on 08/08/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/10/2017 | 10-Q | 10-Q filing on 05/10/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/07/2017 | 10-K | 10-K filing on 03/07/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/14/2016 | 10-Q | 10-Q filing on 11/14/2016 | View Form |
|
PTGX
Protagonist Therapeutics
|
09/15/2016 | 10-Q | 10-Q filing on 09/15/2016 | View Form |
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 1.36% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.63% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.53% over the past day.
